[go: up one dir, main page]

MA31664B1 - Formulations orales de liberation commandee de composes de modulation de canal ionique et procedes associes pour prevenir l'arythmie - Google Patents

Formulations orales de liberation commandee de composes de modulation de canal ionique et procedes associes pour prevenir l'arythmie

Info

Publication number
MA31664B1
MA31664B1 MA32379A MA32379A MA31664B1 MA 31664 B1 MA31664 B1 MA 31664B1 MA 32379 A MA32379 A MA 32379A MA 32379 A MA32379 A MA 32379A MA 31664 B1 MA31664 B1 MA 31664B1
Authority
MA
Morocco
Prior art keywords
prevention
methods
ion channel
channel modulation
arrhythmias
Prior art date
Application number
MA32379A
Other languages
Arabic (ar)
English (en)
Inventor
Jeffery Jerome Wheeler
Gregory N Beatch
Original Assignee
Cardiome Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardiome Pharma Corp filed Critical Cardiome Pharma Corp
Publication of MA31664B1 publication Critical patent/MA31664B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)

Abstract

L'INVENTION CONCERNE DES PROCÉDÉS DE TRAITEMENT ET DE PRÉVENTION DE L'ARYTHMIE ET D'AUTRES MALADIES OU TROUBLES, EN UTILISANT DES COMPOSÉS DE MODULATION DE CANAL IONIQUE, Y COMPRIS LE CHLORHYDRATE DE VERNAKALANT. LA PRÉSENTE INVENTION FOURNIT EN OUTRE DES FORMULATIONS DE LIBÉRATION COMMANDÉE ET DES DOSAGES ORAUX DE CHLORHYDRATE DE VERNAKALANT, QUI SONT EFFICACES DANS LA PRÉVENTION DE L'ARYTHMIE. CERTAINS PROCÉDÉS ET FORMULATIONS DE LA PRÉSENTE INVENTION CONVIENNENT POUR LE TRAITEMENT ET LA PRÉVENTION DE L'ARYTHMIE ET DE TOUTE AUTRE MALADIE OU TROUBLES CHEZ DES SUJETS IDENTIFIÉS COMME UN MÉTABOLISME MÉDICAMENTEUX MODIFIÉ EN RAISON DU POLYMORPHISME DU GÈNE CODANT POUR LE CYTOCHROME P450 2D6.
MA32379A 2007-05-04 2009-11-26 Formulations orales de liberation commandee de composes de modulation de canal ionique et procedes associes pour prevenir l'arythmie MA31664B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US91612907P 2007-05-04 2007-05-04
US6615607P 2007-08-01 2007-08-01
US3411908P 2008-03-05 2008-03-05
US3719808P 2008-03-17 2008-03-17
PCT/US2008/062551 WO2008137778A2 (fr) 2007-05-04 2008-05-02 Formulations orales de libération commandée de composés de modulation de canal ionique et procédés associés pour prévenir l'arythmie

Publications (1)

Publication Number Publication Date
MA31664B1 true MA31664B1 (fr) 2010-09-01

Family

ID=39691347

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32379A MA31664B1 (fr) 2007-05-04 2009-11-26 Formulations orales de liberation commandee de composes de modulation de canal ionique et procedes associes pour prevenir l'arythmie

Country Status (19)

Country Link
US (3) US20080312309A1 (fr)
EP (3) EP2462933A1 (fr)
JP (1) JP2010526102A (fr)
KR (1) KR20100017648A (fr)
CN (1) CN101711174A (fr)
AU (1) AU2008247508B2 (fr)
BR (1) BRPI0810697A2 (fr)
CA (1) CA2686396A1 (fr)
CO (1) CO6241136A2 (fr)
CR (1) CR11117A (fr)
EA (1) EA200971025A1 (fr)
EC (1) ECSP099777A (fr)
IL (1) IL201934A0 (fr)
MA (1) MA31664B1 (fr)
MX (1) MX2009011929A (fr)
NI (1) NI200900196A (fr)
NZ (1) NZ581351A (fr)
TN (1) TN2009000461A1 (fr)
WO (1) WO2008137778A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090041841A1 (en) * 2003-05-02 2009-02-12 Cardiome Pharma Corp. Controlled release tablet formulations for the prevention of arrhythmias
US7345086B2 (en) * 2003-05-02 2008-03-18 Cardiome Pharma Corp. Uses of ion channel modulating compounds
US20110198492A1 (en) * 2010-02-18 2011-08-18 Black David L Detection and Quantitation of Pain Medications in Oral Fluid Specimens

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2103756T3 (es) * 1990-06-22 1997-10-01 Hoffmann La Roche Deteccion de metabolizadores ineficaces de farmacos.
US5891696A (en) 1996-08-02 1999-04-06 Panvera Corporation Compositions for cytochrome P450 biotransformation reactions
JP3176342B2 (ja) 1997-08-13 2001-06-18 ファイザー製薬株式会社 薬剤代謝の評価方法及び前記方法用の試薬組成物
EP1422217A3 (fr) * 1998-04-01 2004-06-16 Cardiome Pharma Corp. Composés aminocyclohexyle ether et leur utilisation
US7507545B2 (en) * 1999-03-31 2009-03-24 Cardiome Pharma Corp. Ion channel modulating activity method
US7057053B2 (en) 2000-10-06 2006-06-06 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US7524879B2 (en) * 2000-10-06 2009-04-28 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
EP1281755A3 (fr) * 2001-07-31 2003-06-18 Pfizer Products Inc. Variants du gène humain cyp2d6
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
US20090041841A1 (en) * 2003-05-02 2009-02-12 Cardiome Pharma Corp. Controlled release tablet formulations for the prevention of arrhythmias
US7345086B2 (en) * 2003-05-02 2008-03-18 Cardiome Pharma Corp. Uses of ion channel modulating compounds
PL227937B1 (pl) * 2003-05-02 2018-01-31 Cardiome Pharma Corp Sposób wytwarzania związku typu eteru aminocykloheksylowego, związek typu eteru aminocykloheksylowego, jego kompozycja, sposób modulowania aktywności kanałów jonowych, oraz zastosowanie związku typu eteru aminocykloheksylowego do wytwarzania leku
CA2524034A1 (fr) * 2003-05-02 2004-11-18 Cardiome Pharma Corp. Utilisations de composes modulant les canaux ioniques
US20080063707A1 (en) * 2003-05-02 2008-03-13 Cardiome Pharma Corp. Controlled release tablet formulations for the prevention of arrhythmias
US7674820B2 (en) * 2003-08-07 2010-03-09 Cardiome Pharma Corp. Ion channel modulating activity I
US7345087B2 (en) 2003-10-31 2008-03-18 Cardiome Pharma Corp. Aminocyclohexyl ether compounds and uses thereof
US7705036B2 (en) * 2004-04-01 2010-04-27 Cardiome Pharma Corp. Deuterated aminocyclohexyl ether compounds and processes for preparing same
EP1868598B1 (fr) * 2004-11-08 2014-04-23 Cardiome Pharma Corp. Schemas posologiques pour modulateurs de canaux ioniques pour le traitement de la fibrillation auriculaire aigue chez l'homme
CA2612375C (fr) * 2005-06-15 2013-08-06 Cardiome Pharma Corp. Procedes synthetiques de preparation de composes d'ether aminocyclohexyle
WO2009018547A1 (fr) * 2007-08-01 2009-02-05 Cardiome Pharma Corp. Formulations à libération prolongée pour la prévention d'arythmies

Also Published As

Publication number Publication date
AU2008247508A1 (en) 2008-11-13
AU2008247508B2 (en) 2014-07-10
CN101711174A (zh) 2010-05-19
NZ581351A (en) 2012-07-27
US20160089361A1 (en) 2016-03-31
EP2462933A1 (fr) 2012-06-13
EP2468278A1 (fr) 2012-06-27
JP2010526102A (ja) 2010-07-29
EA200971025A1 (ru) 2010-04-30
CR11117A (es) 2010-02-19
MX2009011929A (es) 2010-03-08
ECSP099777A (es) 2010-02-26
EP2155334A2 (fr) 2010-02-24
WO2008137778A2 (fr) 2008-11-13
BRPI0810697A2 (pt) 2019-08-27
WO2008137778A3 (fr) 2009-03-12
IL201934A0 (en) 2010-06-16
KR20100017648A (ko) 2010-02-16
NI200900196A (es) 2010-03-11
US20080312309A1 (en) 2008-12-18
CO6241136A2 (es) 2011-01-20
US20150099788A1 (en) 2015-04-09
CA2686396A1 (fr) 2008-11-13
TN2009000461A1 (en) 2011-03-31

Similar Documents

Publication Publication Date Title
NO20073183L (no) Tetrahydrokinolinanalgoer som muskariniske agonister
WO2006105516A3 (fr) Compositions et procedes pour le diagnostic et le traitement de troubles neuropsychiatriques
MA31260B1 (fr) 3-imidazolyl-indoles pour le traitement de maladies proliferatives
MA31027B1 (fr) INHIBITEURS DE L'ACTIVITE Akt
MXPA04006280A (es) Compuestos espiroazaciclicos como moduladores de receptor de monoamina.
MA30340B1 (fr) Nouveaux composes
WO2008151803A3 (fr) Nouveaux polymorphismes du gène abcb1 associés à une absence de réaction clinique à des médicaments
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
DE602004024572D1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
MX2011010353A (es) Composicion farmaceutica.
WO2006044497A3 (fr) Composes de spiropiperidine utilises comme inhibiteurs de beta-secretase en vue du traitement de la maladie d'alzheimer
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
WO2005019258A3 (fr) Compositions et methodes de traitement de maladies relatives au systeme immunitaire
TW200728305A (en) Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease
WO2005004802A3 (fr) Inhibiteurs de la beta-secretase a base de n-alkyle phenylcarboxamide pour le traitement de la maladie d'alzheimer
WO2005032471A3 (fr) Inhibiteurs de type benzylether et benzylamino de beta-secretase pour le traitement de la maladie d'alzheimer
MX2009006345A (es) Compuestos utiles como inhibidores de proteina cinasa.
EP2192901A4 (fr) Agents chimiques, compositions et procédés de traitement et de prévention des infections à orthopoxvirus et des maladies associées
EP2091328A4 (fr) Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer
PL1638938T3 (pl) Związki, kompozycje i sposoby do leczenia i zapobiegania infekcjom ortopokswirusami i powiązanym chorobom
BG108941A (en) Polymorph of acid 4-[2-[4-[1-(2-ethoxyethyl)-1h-benzimidazole-2-il]-1-piperidinyl]ethyl]-alpha, alpha-dimethyl-benzeneacetic
NO20090402L (no) Glysintransportor-1-inhibitorer
WO2006078576A3 (fr) Inhibiteurs de la $g(b)-secretase d'aminomethyle dans le traitement de la maladie d'alzheimer
MA31664B1 (fr) Formulations orales de liberation commandee de composes de modulation de canal ionique et procedes associes pour prevenir l'arythmie
WO2008112840A3 (fr) Nouvelle composition et nouveaux procédés de traitement des maladies immunologiques